1. Home
  2. Media
  3. News
  4. Plan Profarma recognises Bioiberica’s commitment to R&D in Spain

Plan Profarma recognises Bioiberica’s commitment to R&D in Spain

15 Apr 2019
  • The Profarma committee released their ratings for the pharmaceutical sector firms
  • Bioiberica keeps the “good” rating within the A Group (those companies with significant research activity and having their own production plant or basic/pre-clinical R&D center)

The Profarma plan is a joint initiative of the Ministries of Industry, Energy and Consumption, Economics, and Healthcare. Its main aim is to increase the competitiveness of the Spanish pharmaceutical industry through the sector’s modernization and the reinforcement of those activities that contribute higher added value, encourage a change of production models, and improve the balance of payments and the overall GDP. PROFARMA publically recognizes the efforts and commitment to R&D of the leading companies of the sector, the search for new markets, their contribution to the development of industrial and productive activity networks.

Bioiberica is a global life science company committed to improving people, animal, and plant health and well-being. It is the leading Heparin API manufacturer and a world leader in the research, production and marketing of other animal-derived ingredients, such as chondroitin sulfate, glucosamine, hyaluronic acid, type II native collagen, or thyroid.